< 回列表
Takafumi Koyama
- Head of Physician, Department of Experimental Therapeutics, National Cancer Center Japan, Japan
Emerging Targets for Next-Generation Antibody-Drug Conjugate Development
| 角色 | 講師 |
| 日期時間 | 05/03 11:10 - 11:50 |
| 地點 | 701A |
學歷 / 訓練
2006, M.D., Kanazawa University School of Medicine, Ishikawa, Japan
2022, PhD., Chiba University School of Medicine, Chiba, Japan
專業與研究經歷
2022 - Present, Head of Physician, Department of Experimental Therapeutics, National Cancer Center Japan
2018 - 2022, Attending Physician, Department of Experimental Therapeutics, National Cancer Center Japan
2016 - 2018, Clinical Fellow, Department of Experimental Therapeutics, National Cancer Center Japan
2011 - 2016, Attending Physician, Kameda Medical Center, Kamogawa City
2008 - 2011, Clinical Fellow, Kameda Medical Center, Kamogawa City
獲獎與榮譽
2014
Best teaching Award, at Annual meeting of Japanese Society of Internal Medicine
重要出版品
- Liu J, Farrow M, Seymour L, Desai J, Loong HH, Ivy P, Koyoma T, Cook N, Blagden S, Garralda E, Massard C, Tolcher AW, Adashek JJ, Zhang L, Zhao S, Shen L, Kurzrock R, El-Deiry WS, Subbiah V, Joshua AM: Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. J Clin Oncol:Jco2401534, 2025
- Sunami K, Naito Y, Saigusa Y, Amano T, Ennishi D, Imai M, Kage H, Kanai M, Kenmotsu H, Komine K, Koyama T, Maeda T, Morita S, Sakai D, Hirata M, Ito M, Kozuki T, Sakashita H, Horinouchi H, Okuma Y, Takashima A, Kubo T, Hironaka S, Segawa Y, Yakushijin Y, Bando H, Makiyama A, Suzuki T, Kinoshita I, Kohsaka S, Ohe Y, Ishioka C, Yamamoto K, Tsuchihara K, Yoshino T: A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA Oncol 10:95-102, 2024
- Koyama T, Yonemori K, Shimizu T, Sato J, Kondo S, Sudo K, Yoshida T, Katsuya Y, Imaizumi T, Enomoto M, Seki R, Yamamoto N: Phase I Study of Simlukafusp Alfa (FAP-IL2v) with or without Atezolizumab in Japanese Patients with Advanced Solid Tumors. Cancer Res Commun 4:2349-2358, 2024
- Koyama T, Shimizu T, Kojima Y, Sudo K, Okuma HS, Shimoi T, Ichikawa H, Kohsaka S, Sadachi R, Hirakawa A, Yoshida A, Ando RM, Ueno T, Yanagaki M, Matsui N, Nakamura K, Yamamoto N, Yonemori K: Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study. Cancer Discov 13:1814-1825, 2023
- Koyama T, Shimizu T, Iwasa S, Fujiwara Y, Kondo S, Kitano S, Yonemori K, Shimomura A, Iizumi S, Sasaki T, Furuse J, Yamamoto N: First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. Cancer Sci 111:571-579, 2020